Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BIA Wants More Brexit Clarity From UK Regulator As Odds Narrow On ‘No-Deal’ Outcome

Executive Summary

The BioIndustry Association is concerned about the lack of clarity on future UK-EU drug regulation after EU heads of state failed to make any tangible progress on Brexit at their much heralded end-of-June summit.

You may also be interested in...



EMA To Contact Sponsors Of Over 100 Drugs At Risk Of Shortage Post Brexit

The European Medicines Agency’s survey on industry’s preparedness for Brexit has raised serious concerns about the continued supply of 108 drugs that have manufacturing operations based solely in the UK.

No EMA Membership For UK After Brexit, Says European Council

The European Council’s draft guidelines on the future UK-EU relationship say that the UK, as a third country outside the EU single market, will not be able to participate in any EU agencies after Brexit, dashing hopes expressed by the government that the UK could have “associate membership” of the EMA. However, the UK BioIndustry Association remains optimistic that some form of regulatory cooperation can be negotiated in the interests of all stakeholders.

Coronavirus Notebook: EMA Issues New COVID-19 Vaccine Safety Updates, Australia Assesses Comirnaty In Younger Children

The European regulator has warned of the risk of myocarditis, pericarditis and anaphylaxis with Novavax’s COVID-19 vaccine, Nuvaxovid, while Switzerland has updated its guidance on the use of COVID-19 medicines against virus variants. Iconovo has received funding to develop its ICOone nasal inhaler for use in pandemics in resource-poor settings.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS123410

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel